SCHEMBL8606

SCHEMBL8606

CCN(CC)C(C)CC[O]

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2565949 0.82 FDPS (0.33) FDPS
SCHEMBL10371246 0.78
SCHEMBL1612949 0.77 TSHR (0.35) FDPS
SCHEMBL8706 0.77
SCHEMBL10285142 0.77 TSHR (0.35) FDPS
SCHEMBL2565897 0.77 OPRM1 (0.33) FDPS
SCHEMBL2565496 0.77 FDPS (0.31) FDPS
SCHEMBL5692103 0.72 GABRR1 (0.33)
SCHEMBL10367595 0.72 KDM4E (0.32)
SCHEMBL5949130 0.72 DNM1 (0.38) FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047278-A1 Novel Combinational Use of Sulfonamide Compound EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-02-19 US disclosed
EP-1859793-A1 NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-11-28 EP disclosed
EP-0889362-B1 Photopolymerizable composition and dry film resist SHOWA DENKO KK (JP) 2003-08-27 EP disclosed
US-6033829-A THERMOPLASTIC COPOLYMER OF AN ALPHA, BETA-UNSATURATED CARBOXYL GROUP-CONTAINING MONOMERS AND ANOTHER MONOMER; A CROSSLINKING MONOMER; AND A POLYMERIZATION INITIATOR COMPRISING A QUATERNARY BORON SALT AND A SENSITIZING DYE SHOWA DENKO K.K. (JP) 2000-03-07 US disclosed
US-5932574-A ANTICANCER AGENT ZENECA LIMITED (GB) 1999-08-03 US disclosed
EP-0889362-A1 Photopolymerizable composition and dry film resist SHOWA DENKO KABUSHIKI KAISHA (JP) 1999-01-07 EP disclosed
US-5770599-A RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) ZENECA LIMITED (GB) 1998-06-23 US disclosed
EP-0824525-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1998-02-25 EP disclosed
EP-0823900-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1998-02-18 EP disclosed
WO-1996033980-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1996-10-31 WO disclosed
WO-1996033977-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1996-10-31 WO disclosed
US-4536512-A 5-(2,3-Dihydro-1H-pyrrolizin-5-oyl)-2,3-dihydro-1H-pyrrolizine-1-alkanoic or carboxylic acids and use thereof as anti-inflammatory and analgesic agents MERCK & CO., INC. (US) 1985-08-20 US disclosed
US-4533671-A 5-(2,3-Dihydro-1H-pyrrolizin-5-oyl)-2-alkanoic or carboxylic acids and analogs as anti-inflammatory and analgesic agents MERCK & CO., INC. (US) 1985-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047278-A1 Novel Combinational Use of Sulfonamide Compound EGFR, KIT, ERBB2 FDPS 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.